Abstract CT162: Analysis of tumor and biomarker responses in the VIRAGE Trial, a randomized Phase IIb, open-label, study of nab-paclitaxel and gemcitabine with/without intravenous VCN-01 in patients with metastatic pancreatic cancer (mPDAC)
Year: 2026
Type: conference-abstract
Source: Cancer Research
Authors: Rocio Garcia-Carbonero, Roberto Pazo, Teresa Macarulla, Berta Laquente, Alana Nguyen, Carmen Guillén-Ponce, Andres J. Muñoz, Edward J. Kim, Mireya Cazorla, Tara Seery, Miriam Lobo de Mena, Chris Nevala-Plagemann, Vivek R. Sharma, Eva Martinez de Castro, Charles Le, Ana Mato-Berciano, Luis A. Rojas, Carmen Blasco, Manel Cascallo, Manuel Hidalgo
Institutions: Hospital Universitario 12 De Octubre, Hospital Universitario Miguel Servet, Vall d'Hebron Hospital Universitari, Institut Català d'Oncologia, Cornell University, Weill Cornell Medicine, Weill Cornell Medical Center, Hospital Universitario Ramón y Cajal, Hospital General Universitario Gregorio Marañón, UC Davis Comprehensive Cancer Center, Hospital Regional Universitario de Málaga, Hoag Memorial Hospital Presbyterian, Hospital General Universitario De Valencia, University of Utah, Huntsman Cancer Institute, University of Louisville, Marqués de Valdecilla University Hospital, Theriva Biologics (United States), NYU Langone Health, NYU Langone’s Laura and Isaac Perlmutter Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7154754027
Cites:
Cited by:
Related to: